Research Analysts Offer Predictions for BOLT Q3 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Bolt Biotherapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.79 million.

Separately, Stifel Nicolaus cut their price objective on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Stock Up 4.8 %

BOLT opened at $0.44 on Thursday. The company has a market cap of $16.84 million, a PE ratio of -0.26 and a beta of 0.94. Bolt Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.56. The company has a 50-day moving average price of $0.47 and a 200 day moving average price of $0.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of the business. FMR LLC grew its stake in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after acquiring an additional 28,773 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $25,000. Squarepoint Ops LLC purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at approximately $26,000. Velan Capital Investment Management LP acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at approximately $27,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at approximately $42,000. 86.70% of the stock is currently owned by institutional investors and hedge funds.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.